Skip to main content

Advertisement

Table 3 Baseline early cancer presence and result

From: Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84

   ENOX2 present Transcript variant Retest Post intervention
   MW pH   months MW pH
1. 57 F 55 4.2 Colorectal 14 Negative  
   38 4.0     
2. 64 F Negative      
3. 45 F Negative      
4. 51 F Negative      
5. 71 M 58 4.0 Mesothelioma (Mesothelium) 9 Negative  
40 3.9
6. 58 M 54 5.1 Non-small cell lung 7 Negative  
7. 59 F 75 4.8 Ovarian 8 Negative  
40 4.6
8. 61 F Negative      
9. 81 F Negative      
10. 55 F Negative      
11. 68 F 64 4.2 Breast 7 Negative  
12. 52 M 54 5.0 Non-small cell lung 12 Negative  
13. 45 F Negative      
14. 46 F Negative      
15. 73 F 80 4.5 Ovarian 7 Negative  
38 4.1
16. 54 F Negative      
17. 63 F Negative      
18. 75 F 66 4.2 Breast 6 Negative  
19. 53 M Negative      
20. 67 F 80 4.6 Colorectal 7 Negative  
52 5.1
21. 73 M Negative      
22. 70 M Negative      
23. 61 F Negative      
24. 50 F 54 5.2 Non-small cell lung 22 54 5.2
25. 54 F 64 4.2 Breast 8 Negative  
26. 84 M 54 5.2 Non-small cell lung 5 Negative  
27. 59 F Negative      
28. 74 M 56 4.8 Non-small cell Lung 4 Negative  
29. 64 F 58 4.5 Colorectal   No retest  
40 4.4
30. 61 M Negative      
31. 52 F Negative      
32. 83 M Negative      
33. 75 M Negative      
34. 51 F 43 3.8 Blood cell 17 Negative  
35. 71 F Negative      
36. 65 M Negative      
37. 50 F Negative      
38. 47 M 39 4.4 Blood cell 12 Negative  
39. 54 F 50 5.1 Colorectal 12 Negative  
38 3.8
40. 71 M 54 5.1 Non-small cell lung   No retest  
41. 79 M 120 4.5 Not in data base 7 Negative  
34 5.2
42. 75 M Negative      
43. 59 M 60 5.1 Squamous cell 7 Negative  
44. 52 F Negative      
45. 63 F 35 4.0 Generic ENOX2 14 64 5.1
46. 60 F Negative      
47. 58 F Negative      
48. 61 F 68 4.4 Breast   No retest  
49. 52 F 42 3.9 Blood cell   No retest  
50. 76 M Negative      
51. 54 F Negative      
52. 54 F Negative      
53. 63 F 55 5.0 Non-small cell lung   No retest  
54. 52 F Negative      
55. 56 F Negative      
56. 49 F 92 4.6 Cervical 3 Negative  
57. 54 F Negative      
58. 58 M 88 5.1 Prostate   No retest  
59. 68 F 68 4.2 Breast 8 Negative  
60. 49 F Negative      
61. 50 F Negative      
62. 64 F Negative      
63. 62 M 33 4.2 Generic ENOX2 9 Negative  
64. 50 F Negative      
65. 50 M 40 5.0 Melanoma   No retest  
66. 72 F 64 4.6 Breast   No retest  
67. 49 F Negative      
68. 50 F Negative      
69. 54 F 54 5.0 Non-small cell lung   No retest  
70. 73 M Negative      
71. 49 F Negative      
72. 81 F Negative      
73. 47 F 75 4.1 Ovarian   No retest  
46 4.0
74. 48 M 80 4.2 Not in data base 9 Negative  
75. 56 F Negative      
76. 46 M Negative      
77. 54 F 67 4.5 Uterine 3 Negative  
39 4.9
78. 54 F Negative      
79. 65 M Negative      
80. 55 M 68 4.0 Not in data base 9 Negative  
81. 60 M 83 5.7 Prostate 12 Negative  
82. 80 F Negative      
83. 58 M 71 5.5 Prostate 12 Negative  
84. 83 M Negative      
85. 53 M Negative      
86. 78 F Negative      
87. 40 F 90 5.4 Cervical 6 Negative  
88. 64 M Negative      
89. 56 M Negative      
90. 62 F 65 4.2 Breast   No retest  
91. 52 F Negative      
92. 57 F 58 4.6 Papillary thyroid 7 Negative  
44 3.7
93. 52 F Negative      
94. 67 M Negative      
95. 70 M Negative      
96. 46 M 68 5.1 Squamous cell 24 Negative  
97. 52 F Negative      
98. 56 F Negative      
99. 53 M Negative      
100. 59 M 54 4.8 Non-small cell lung   No retest  
101. 66 M Negative      
102. 70 F Negative      
103. 59 M Negative      
104. 77 F 92 5.1 Cervical 4 Negative  
105. 68 M Negative      
106. 62 M Negative      
107. 58 F Negative      
108. 78 F 66 4.6 Bladder 3 Negative  
44 4.6
109. 62 M Negative      
110. 65 M Negative